Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Vericel Reports 22% Revenue Rise, Raises 2026 Guidance, Initiates $200M Buyback

Jul 30, 2026, 7:57 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Raised guidance, a substantial buyback, and a strong balance sheet typically drive multiple expansion and investor optimism; Vericel has historically rewarded guidance upgrades and capital returns when fundamentals remain solid (MACI growth, NexoBrid cadence).

AI summary

What happened, with direct paths to the underlying reporting

Vericel posted Q2 2026 revenue of $77.5M, up 22%, led by MACI. The company raised full-year revenue guidance to $330-340M and authorized a $200M share repurchase, signaling strong cash flow and balance-sheet strength with potential upside from international expansion. NexoBrid and Epicel momentum also supports ongoing growth.

Total revenue rose 22% to $77.5M. MACI revenue grew 23% to $65.5M.
Net income $2.2M; free cash flow $14.3M; cash and investments ~$227M, no debt.
2026 revenue guidance raised to $330-340M; MACI $284-290M; Burn Care $46-50M.
Board authorized a $200M share repurchase program.
UK MHRA MACI marketing authorization application submitted; NexoBrid and Epicel momentum highlighted.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.